Vorinostat May Not Improve Survival in Mesothelioma

Share this content:
Vorinostat as second- or third-line therapy may not improve overall survival in advanced malignant pleural mesothelioma.
Vorinostat as second- or third-line therapy may not improve overall survival in advanced malignant pleural mesothelioma.

Vorinostat as second- or third-line therapy may not improve overall survival in patients with advanced malignant pleural mesothelioma, according to a recent study published online ahead of print in The Lancet Oncology.

Lee M. Krug, MD, of the Memorial Sloan-Kettering Cancer Center and fellow researchers randomized 661 patients with measurable mesothelioma who had disease progression after one or two previous systemic regimens to either vorinostat or placebo.

Primary endpoint was overall survival as well as safety and tolerability of vorinostat.

They found that median overall survival for vorinostat was 30.7 weeks compared to 27.1 weeks with placebo.

RELATED: Hyponatremia May Be Negative Prognostic Parameter for Malignant Mesothelioma

Common grade 3 or worse adverse events included 51 patients with fatigue or malaise in the vorinostat group compared to 25 with placebo.

“In this randomized trial, vorinostat given as a second-line or third-line therapy did not improve overall survival and cannot be recommended as a therapy for patients with advanced malignant pleural mesothelioma,” the authors concluded.

Reference

  1. Krug, Lee M., MD, et al. "Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial." The Lancet Oncology. DOI: http://dx.doi.org/10.1016/S1470-2045(15)70056-2. [epub ahead of print]. March 19, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters